BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 24, 2026
AI-Generated Deep Dive Summary
BridgeBio Pharma (BBIO) delivered a strong financial performance in its Q4 2025 earnings call, driven by robust revenue growth and expanding commercial momentum for its lead product Atruby. The company reported $154.2 million in total quarterly revenue, marking a significant year-over-year increase from $5.9 million. This surge was fueled by $146 million in net product revenue from Atruby, alongside contributions from royalty, license, and service revenues. Full-year 2025 revenue totaled $502.1 million, up nearly 135% year-over-year, reflecting the drug's growing market share and patient adoption. The company also highlighted its cash position, ending the year with $587.5 million in cash equivalents, bolstered by a recent convertible note issuance.
The success of Atruby was evident in its clinical and commercial performance. With over 7,800 unique patient prescriptions written by 1,856 prescribers as of February 2026, the product achieved a net patient retention rate exceeding 25
Verticals
financeinvesting
Originally published on The Motley Fool on 2/24/2026